In the past 4 years, sodium glucose cotransporter 2 inhibitors (SGLT2i) have been shown to have a high ability to intervene in the progression of DKD in the EMPA‐REG Outcome (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes) study, CANagliflozin cardioVascular Assessment Study (CANVAS) program and DECLAIR TIMI 58 (Dapagliflozin Effect on CardiovascuLAR Events) study11. Here, SLC5A2 is linked to diabetic kidney disease.